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Abstract: Sexual dysfunction is a common side effect of antidepressants and can have significant 
impact on the person’s quality of life, relationships, mental health, and recovery. The reported 
incidence of sexual dysfunction associated with antidepressant medication varies considerably 
between studies, making it difficult to estimate the exact incidence or prevalence. The sexual 
problems reported range from decreased sexual desire, decreased sexual excitement, diminished 
or delayed orgasm, to erection or delayed ejaculation problems. There are a number of case 
reports of sexual side effects, such as priapism, painful ejaculation, penile anesthesia, loss of 
sensation in the vagina and nipples, persistent genital arousal and nonpuerperal lactation in 
women. The focus of this article is to explore the incidence, pathophysiology, and treatment of 
antidepressant iatrogenic sexual dysfunction.
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Introduction
Sexual dysfunction is a common side effect of antidepressants, particularly of selective 
serotonin reuptake inhibitor (SSRIs) and serotonin norepinephrine reuptake inhibitor 
(SNRIs) medications. Sexual dysfunction can have significant impact on the person’s 
quality of life, quality of relationships, self esteem, and recovery and can lead to 
noncompliance with antidepressant treatment with a potential for relapse of symptoms.1 
Despite this and the frequency of researchers reporting antidepressant-associated sexual 
dysfunction within the literature, it continues to be underreported or underemphasized 
on client information leaflets, package inserts,2 and verbal information given to clients 
by practitioners.3
During the 60s and 70s, reports of antidepressant-associated sexual dysfunction 
were rare;4 possibly due to underreporting, lack of discussion and assessment, and 
an assumption that people with mental health problems were asexual and lacked 
any sexual desire.5 The increased recognition of drug induced sexual dysfunction 
is multifaceted: including a greater willingness on behalf of researchers to include 
questions on sexual function and sexual desire; use of antidepressants for other 
conditions in a population that does not have a mental health problem; greater focus 
on service users views and quality of life issues; and as Balon4 suggests, market-
ing competition among pharmaceutical companies. The focus of this article is to 
explore the incidence, pathophysiology, and treatment of antidepressant-associated 
sexual dysfunction.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Incidence of antidepressant-
associated sexual dysfunction
Pharmacotherapy of depression involves the use of antide-
pressants which modulate central neurotransmitter levels, 
namely serotonin, norepinephrine, and dopamine. The main 
classes of antidepressants are the tricyclic antidepressants 
(TCAs), SSRIs, SNRIs, monoamine oxidase inhibitors 
(MAOIs), and the atypical antidepressants.
Treatment-emergent sexual dysfunction has been 
reported with virtually all of the antidepressants. The 
reported incidence of sexual dysfunction associated with 
antidepressant medication varies considerably between 
studies, making it difficult to estimate the exact incidents 
or prevalence. Rothschild6 in a review of research studies 
on antidepressants and sexual function concluded that 40% 
of people taking antidepressants will develop some form 
of sexual dysfunction. Studies estimate that the incidence 
varies from 30% of people treated with imipramine7 to 
25%–73% of people treated with an SSRI,8–11 with 93% 
of the men and women treated with clomipramine in 
one study complaining of total or partial anorgasmia.12 
Montjo-Gonzales et al10 reported an overall incidence of 
58% in an unblinded study involving 344 clients who had 
a history of normal sexual function before SSRI treatments. 
The frequency of sexual side effects was highest for 
paroxetine (65%), fluvoxamine (59%), sertaline (56%) and 
fluoxetine (54%). In a multicenter, prospective, Spanish 
study involving 1022 people, Montejo et al12 reported a 
59.1% overall incidence of sexual dysfunction when all 
antidepressants were considered as a whole. The differences 
between drugs are summarized in Table 1 and were as 
follows: incidence of sexual dysfunction with SSRIs and 
venlafaxine (an SNRI) were high ranging between 58% and 
70% – fluoxetine (57.7%), sertaline (62.9%), fluvoxamine 
(62.3%), venlafaxine (67%), paroxetine (70.7%), and 
citalopram (72.7%). This compared with a much lower 
incidence for the newer 5-HT2 blockers (8% nefazodone 
and 24% mirtazapine). Moclobemide, a reversible 
MAOI, (3.9%) resulted in the lowest incidence of sexual 
dysfunction. When differences between men and women 
were compared, men reported a slightly higher frequency 
of sexual dysfunction than women (62% and 60%). Clayton 
et al,13 in an adult outpatient population (4534 women 
and 1763 men) receiving antidepressant monotherapy, 
reported rates of sexual dysfunction as follows: mirtazapine 
and venlafaxine extended release were associated with 
higher rates (36%–43%), followed by nefazodone (28%), 
bupropion SR (25%) and bupropion IR (22%).
Modell et al11 investigated through self-reported 
anonymous questionnaires, the sexual side effects of bupro-
pion and the SSRIs (fluoxetine, paroxetine, and sertraline) 
among 107 outpatients. Overall, 73% of the SSRI-treated 
clients reported adverse sexual side effects; in contrast, to 14% 
of clients treated with bupropion. The three SSRIs, to an equal 
degree, significantly decreased libido, arousal, duration of 
orgasm, and intensity of orgasm below levels experienced pre-
morbidly. In comparison, bupropion-treated clients reported 
significant increases in libido, level of arousal, intensity of 
orgasm, and duration of orgasm beyond levels experienced 
premorbidly. Consequently, the authors concluded that adverse 
sexual effects appear to be the rule rather than the exception 
with SSRIs. In a similar study, Kennedy et al8 compared the 
effects of moclobemide, paroxetine, sertraline, and venla-
faxine on drive/desire and arousal/orgasm. Similar to other 
studies, rates of sexual dysfunction were higher for sertraline, 
paroxetine, and venlafaxine, when compared with moclobe-
mide. Compared with women, men experienced a significantly 
greater level of impairment in drive/desire, whereas no differ-
ence was reported in levels of arousal/orgasm. No difference 
was found across the four antidepressants in men, whereas 
rates of sexual dysfunction were higher in women who were 
prescribed with sertraline and paroxetine.
A number of double blind comparative studies without 
placebo control have also been conducted. Kavoussi et al14 
in a randomized double-blind study, of 248 people with 
moderate to severe depression, compared sustained-release 
bupropion and sertraline on sexual function. They reported 
that orgasmic dysfunction was significantly (P , 0.001) 
more common in the sertraline-treated group. During the 
16-week trial, 61% men and 41% of women treated with 
sertaline reported orgasmic dysfunction, compared with 10% 
men and 7% of women in the bupropion. Segraves et al15 
also compared the effects of sustained-release bupropion and 
sertraline on sexual function, in 240 people with moderate 
to severe depression. They reported similar results, with a 
significantly greater percentage of sertraline-treated clients 
(63% and 41% of men and women, respectively) developed 
sexual dysfunction compared with bupropion SR-treated 
clients (15% and 7% of men and women, respectively). 
Sexual dysfunction was noted as early as day 7 in sertraline-
treated clients and persisted until the end of the 16-week 
treatment phase. Four clients, all of whom were treated with 
sertraline, discontinued from the study prematurely because 
of sexual dysfunction. Feiger et al16 compared the effects of 
nefazodone with sertraline in 160 clients with major mood 
disorder.   Findings suggested that for men, overall satisfac-Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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tion with sexual functioning was greater with nefazodone; 
67% of men taking sertraline reported ejaculatory difficulties 
compared with 19% of the nefazodone-treated group. 
In women, nefazodone was superior to sertaline on measure 
of ease of achieving orgasm and satisfaction with orgasmic 
ability. Some years later, Ferguson et al17 in an 8-week 
double-blind study, also compared nefazodone with sertra-
line, this time among 105 people who were experiencing 
sexual dysfunction attributable to sertraline. Clients were 
randomly assigned to either group following a 1-week 
wash out period and a subsequent 7–10-day placebo phase. 
Similar to the previous studies, sertaline-treated clients 
reported more drug-related sexual dysfunction. 76% of the 
sertaline-treated clients experienced reoccurrence of sexual 
dysfunction (ejaculatory or orgasmic difficulty) compared 
with 26% of the nefazodone-treated group. In this study, 5 
of the sertaline-treated clients discontinued therapy because 
of sexual dysfunction.
A small number of double-blind comparative studies 
with placebo control have been conducted. Croft et al1 
compared the effects of sustained-release bupropion, ser-
traline, and placebo on sexual function with 360 people 
with moderate to severe depression. Findings indicated 
that people treated with sertraline experienced signifi-
cantly more sexual dysfunction throughout the duration 
of the study compared with those treated with bupropion 
SR or placebo. Orgasmic dysfunction occurred after 
only 1 week of treatment in sertaline-treated clients and 
continued throughout the 8-week treatment. There were 
no significant differences in the occurrence of orgasmic 
dysfunction between bupropion SR and placebo at any 
time during the study. Coleman et al18 compared the sexual 
function effects of bupropone, fluoxetine, and placebo in 
456 people. Again, decline in sexual functioning, sexual 
desire, and sexual arousal were more frequently associated 
with fluoxetine treatment than with bupropine or placebo. 
These findings support findings from other studies that 
suggest bupropion SR is relatively free of sexual side 
effects,11,19 and supports the contention that bupropion SR 
may be an appropriate antidepressant for clients concerned 
about sexual function.
Within the literature there are also a number of case 
study-anecdotal accounts of other sexual side effects, such 
as: priapism associated with paroxetine;20 painful ejaculation 
associated with venlafaxine,21 reboxetine,22 and tricyclics;23 
loss of sensation in the vagina and nipples;24 penile anesthesia 
associated with fluoxetine25 and sertraline;26 and spontane-
ous ejaculation with reboxetine, an SNRI known for its lack 
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of sexual side effects.27 In addition, decreased nocturnal 
erections have been reported with amitriptyline.28
Over the years, several case reports have been published 
on a relationship between antidepressants and nonpuerperal 
lactation or galactorrhea in women. Egberts et al29 con-
cluded from their analysis of reported drug reactions to 
the Netherlands Pharmacovigilance Foundation, between 
1986 and 1996, that SSRIs and clomipramine were associated 
with approximately eight times higher risk of nonpuerperal 
lactation in women, when compared with women taking 
nonserotonergic antidepressants. Although rare, withdrawal 
syndromes that impact on sexuality and sexual function 
have also been described. In a recent article, Leiblum and 
Goldmeier30 describe persistent genital arousal disorder in 
five women who attribute the onset of their sensations to 
either the usage or discontinuation of an SSRI. The women 
found the sensation distressing, with only brief relief from 
orgasm, and reported that their genital arousal was qualita-
tively different from sexual arousal that is preceded by sexual 
desire and/or subjective arousal.
There are very few studies that examine the impact of 
antidepressants on people without a mental health problem. 
Kowalski et al31 conducted a double-blind trial in a group of 
men without psychiatric diagnosis, to compare the impact 
of amitriptyline, mianserin, and placebo on nocturnal sexual 
arousal. Both amitriptyline and mianserin significantly 
decreased the amplitude and duration of nocturnal erections. 
Kennedy et al32 compared the effects of moclobemide and 
placebo on 60 healthy male and female adults and found no 
difference in the effects on sexual interest or sexual function 
in healthy volunteers. It needs to be remembered, however, 
that moclobemide is an antidepressant with the lowest inci-
dence of reported sexual dysfunction in clients being treated 
for depression.12
Although the research provides firm evidence that antide-
pressant medication is associated with sexual dysfunction in 
both men and women, reaching any firm conclusion about the 
exact prevalence is difficult. Data on the prevalence of sexual 
dysfunction among the general population is scarce making it 
difficult to establish a ‘normal’ baseline.33 In addition, there 
are very few large studies that explored the effects of antide-
pressants on adults without depression, or who used placebo 
controls. In their review of evidence of sexual dysfunction 
associated with antidepressants, Montgomery et al33 describe 
methodological problems such as absence of comparison 
groups, inconsistent definitions of sexual dysfunction, 
absence of baseline assessment of sexual functioning, and 
the use of various measures of sexual functioning as well as 
the questionable validity of the rating scales used. There is 
also a difficulty within the studies in separating sexual dys-
function resulting from depression and that resulting from 
the drugs – as depression itself is associated with decreased 
libido, decreased sexual activity, and decreased erectile and 
orgasmic excitement.34 Balon4 highlights that most studies 
do not take into account other coexisting problems such 
as substance misuse, physical health problems, and other 
medications that may contribute to sexual dysfunction. The 
variation in rates between studies is also possibly due to the 
wide variety of measures used to measure sexual functioning, 
use of different samples, and recruitment strategies. However, 
a number of writers suggest that, in all probability, the dif-
ference in rates is due to substantial underreporting rather 
than under occurrence.8,11
Differential effects of the various 
antidepressant classes and drugs
In general, the mechanisms of action involve either the 
inhibition of breakdown of norepinephrine or blocking the 
reuptake of serotonin and norepinephrine at the presynaptic 
terminal, resulting in increased neurotransmitter availability 
at the synapse.
Sex is more than a physical act. It also includes emotional 
and psychological dimensions. The normal sex cycle con-
sists of four successive phases: desire, arousal, orgasm, and 
resolution.35 These phases are facilitated by the interplay of 
neurotransmitters, hormones, and peptides. Different classes 
of antidepressants impact on all phases of the sexual response 
cycle to varying degrees, and the details pertaining to each 
class of antidepressant are summarized in Table 1.
The challenge is to understand how antidepressants 
impact on normal sexual function. Because most antide-
pressants modulate serotonin concentration, it is generally 
thought that elevated serotonin levels diminish sexual 
function.37 Serotoninergic nerve terminals target dopamine 
and norepinephrine pathways in the brain and inhibit their 
activity,38 both of these neurotransmitters having a role in 
the desire and arousal phases of the sexual response cycle. 
80% of serotonin is localized in the periphery, where when 
elevated, it directly reduces sensation in the anatomical 
structures of the reproductive system as well as diminish-
ing erection, vaginal lubrication, ejaculation, and orgasm.39 
According to Nelson et al,40 the 5HT2 and 5HT3 receptor 
subtypes underlie serotoninergic-mediated sexual dysfunc-
tion. In addition, serotonin inhibits nitric oxide production, 
which normally has a role in relaxing the smooth muscle of 
the vasculature (including the vasculature of the reproductive Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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structures), thus enabling vasodilation and allowing sufficient 
blood supply to the sexual organs during the sexual response 
cycle.41
The autonomic nervous system regulates the mechanistic 
aspects of sexual function (eg, orgasm and ejaculation) and 
utilizes acetylcholine (parasympathetic and sympathetic 
systems) and norepinephrine (sympathetic system). Many 
antidepressants have some efficacy at cholinergic and 
alpha1-adrenergic receptors, thereby inhibiting the autonomic 
nervous system and consequently inhibiting normal sexual 
function.10
Long-term exposure may impact at the genetic level to 
effect functioning of the catecholaminergic and endocrine 
systems,42 such as antidepressant-associated changes to 
semen quality and DNA integrity.43,44
The management of  
antidepressant-associated  
sexual dysfunction
It is estimated that 30% of people treated for depression 
may be noncompliant with treatment; minimization of 
antidepressant-associated sexual dysfunction could be an 
important factor in successful treatment and health out-
comes.18 The management of antidepressant-associated 
sexual dysfunction is complex. Balon4 suggests that “given 
the scarcity of evidence-based treatments the management 
of sexual dysfunction is still an art rather than a science” 
(p. 1506).
As stated earlier, the normal sexual response cycle consists 
of four successive phases: desire, arousal, orgasm, and reso-
lution.35 The management of antidepressant-associated sexual 
dysfunction should endeavor to address sexual dysfunction 
equating to each stage of the sex cycle. However, this is not 
entirely possible as, as Jespersen45 suggests, poor overall 
sexual satisfaction is a common complaint of clients with 
antidepressant-associated sexual dysfunction.
Therefore, the first stage of effective management is 
a thorough assessment to ensure that the reported sexual 
dysfunction is indeed a consequence of antidepressant treat-
ment. This will involve a re-evaluation of the depressive 
episode, including a physical and sexual health assessment. 
As Zajecka46 states, “the first step in management is to define 
the actual complaint and then attempt to determine the aetiol-
ogy” (p. 35). This may not be as easy as it appears.
A thorough assessment will focus on:
•  Eliminating confounding factors for sexual dysfunction, 
eg, age or alcohol/substance use
•  Excluding a comorbid physical complaint, eg, side effects 
of drugs used to manage diabetes or hypertension may 
be a cause of sexual dysfunction.47 Higgins48 states that 
diabetes, atherosclerosis, cardiac disease, central and 
peripheral nervous system disease, and alcoholism can 
also contribute to sexual dysfunction.
•  Excluding ongoing, or residual, symptoms of depression. 
Kennedy et al49 found in a sample of people with major 
depression (55 male and 79 female), over 40% of men 
and 50% of women reported decreased sexual interest 
prior to antidepressant treatment.
The main challenge faced by practitioners is managing 
antidepressant-associated sexual dysfunction without compro-
mising the mental wellbeing of the client. This very fine balanc-
ing act may not be resolved adequately to everyone’s liking. 
Noncompliance may constitute a big problem for practitioners 
as this will have a positive effect on antidepressant-associated 
sexual dysfunction. However, the obvious complication here 
is for relapse into the depressive state. Therefore, practitioners 
must be honest and open with the client in order to build trust, 
which can empower them to make better decisions about both 
their physical health and mental wellbeing.
There are various pharmacological and non-
pharmacological ways of managing antidepressant-
induced sexual dysfunction.
Drug adaption
In most cases, antidepressant regimes may be short term. There-
fore, clients may opt to endure the effects of sexual dysfunction 
for a short period, until their treatment ends. Part of this may 
stem from a perception that their ‘sex life’ not being as bad with 
medication side effects as it was with their depression.
Once initiated, any medication requires a phase of adap-
tion due to the potential unintended, or unforeseen, reactions. 
Drug adaption requires accommodation. Some adverse drug 
reactions, eg, nausea or blurred vision, recede as the client’s 
body adapts to the antidepressant. Therefore, one course of 
management of antidepressant-associated sexual dysfunc-
tion is a ‘wait and see’ approach. Montejo et al12 suggest 
that spontaneous and partial remission of antidepressant-
associated sexual dysfunction occurs in 10% of individuals 
treated with antidepressant agents. However, this still leaves 
a large proportion of individuals who will not spontaneously 
recover, even partially. Therefore this approach will not be 
suitable for all clients.
If antidepressant-associated sexual dysfunction emerges 
rapidly then this phase may be quickly passed over for one 
of the other possibilities.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Reduction in medication dosage
The first point to consider relates to the client’s medication 
regime. Practitioners should ask if the client is on their 
optimum dosage of antidepressant, ie, the optimum to man-
age the client’s illness, not the optimum dosage that can be 
prescribed. This can give a vital space to proceeding with 
reducing medication dosage.
Antidepressant-associated sexual dysfunction may be a 
dose-related adverse event. Therefore reducing the dosage of 
the treatment to a minimum effective dose may be an option. 
However, this carries alternative risk to the client’s mental 
health. While dose reduction is a management option, the 
practitioner must educate the client to be aware that reduc-
tion will not have an immediate effect on the antidepressant-
associated sexual dysfunction. The rate at which the sexual 
dysfunction will recede will depend on the half-life of the 
particular antidepressant. If the client anticipates an immedi-
ate effect on dose reduction and it fails to materialize, the risk 
is that they abstain from their antidepressant regime.
Switching medications
Another strategy is switching antidepressants to one with 
a less risky side effect profile. This may include switching 
from an SSRI to non-SSRI antidepressant. This may give the 
potential benefits of continuing to manage the depressive ill-
ness while reducing the potential for sexual dysfunction.
In a systematic review of strategies for managing sexual 
dysfunction, Rudkin et al50 reported that switching from 
sertraline to nefazodone was significantly less likely to 
result in re-emergence of the sexual dysfunction and was not 
associated with any worsening depression. Zajecka46 sug-
gests that nefazodone, bupropion, and possibly mirtazapine 
have minimal or no negative impact on sexual functioning. 
However, individual responses to this strategy may vary. 
Firstly, the sexual dysfunction may recede but the depressive 
illness reasserts itself. Secondly, the change of medication 
may result in other associated side effects which may be 
more debilitating as they are present throughout the client’s 
day, not just when they want to have sex. Thirdly, the client 
who has experienced both the depression and the sexual 
dysfunction may feel that a ‘little’ depression is preferable 
to sexual dysfunction.
Adjunct treatment
As in most psychotropic medication regimes adjunct treatment, 
introducing another drug to counteract side-effects may be 
required. Clayton et al51 concluded from their double-blind 
comparison study involving 42 clients with SSRI-induced 
sexual dysfunction that bupropion SR was an effective antidote. 
In comparison with placebo, clients treated with bupropion 
SR showed a significantly greater improvement in desire and 
frequency of engaging in sexual activity. Labbate et al52 found 
that bupropion 75 mg q.d. reversed SSRI induced sexual dys-
function. However, this was a small case study with a sample of 
six people (4 female and 2 male). Demyttenaere and Huygens22 
describe the successful treatment of two clients with tamsulosin 
(alpha 1A-adrenoceptor antagonist), who had experienced 
antidepressant-induced painful ejaculation. Michelson et al53 
concluded from their trial that neither buspirone nor amanta-
dine was more effective than placebo in improving fluoxetine-
induced sexual dysfunction in women.
There is evidence from systematic review of randomized, 
controlled trials into the management of antidepressant-
induced sexual dysfunction that the addition of sildenafil 
(Viagra) will improve erectile dysfunction in men.50,54 The 
benefit to women has yet to be comprehensively proven. One 
randomized placebo controlled trial involving 98 women 
experiencing antidepressant induced sexual dysfunction con-
cluded that sildenafil significantly reduced the adverse sexual 
effects, such as delayed orgasm responses and inadequate 
lubrication.55 However, the clinical benefit and risk have yet 
to be proven in large studies.
Alcantara56 states that drugs that act as 5-HT2-receptor 
agonists may cause sexual dysfunction by inhibiting the 
release of dopamine and noradrenaline. They suggest that 
5-HT2 antagonism or strategies that increase noradrenergic 
or dopaminergic transmission may be useful in reversing 
sexual dysfunction.
Adjunct treatments should only be considered following a 
thorough physical assessment of the client and a medication 
review to address any contraindications with current psychotro-
pic medications. Both sildenafil and bupropion have potential 
side effects. Sildenafil is associated with visual disturbances, 
palpitations, hypotension, and priapism, and bupropion may 
cause dry mouth, insomnia, gastrointestinal disturbances, and 
tremor.57 Individuals might perceive these side effects as more 
debilitating than sexual dysfunction. Therefore it is important 
that they have all the information on potential effects of adjunct 
treatments so that they can make informed decisions.
Conflicting evidence on the nature of herbal supplements 
such as ginkgo biloba as an adjunct treatment exists. In an 
open trial, ginkgo biloba was found to be effective in treating 
antidepressant induced sexual dysfunction generally having a 
positive effect on all four phases of the sexual response cycle: 
desire, excitement, orgasm, and resolution.58 The authors 
also note that women were more responsive to the sexually Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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enhancing effects of ginkgo biloba than men. However, 
a group placebo controlled double blind trial of ginkgo biloba 
found no significant difference in sexual functioning in any 
phase, although the placebo group showed improved orgasm 
satisfaction.59 While its mode of action is not yet known,60 
further trials of herbal supplements may be appropriate.
Drug holiday
A drug holiday is a high-risk treatment option where medication 
is omitted on the day of or prior to, anticipated sexual activity. 
While drug holidays are contentious and might not appeal to 
many practitioners, some evidence does exist which suggests 
stopping antidepressant medication on a temporary basis might 
be a potential strategy. In a trial of a drug holiday for SSRI-
induced sexual dysfunction, Rothschild61 instructed 30 outpa-
tients to discontinue their SSRIs after their Thursday morning 
dose and then restart at their previous dose on Sunday at 12:00 
noon over four weekends. They found that clients taking sertra-
line and paroxetine reported a significant improvement in their 
sexual functioning, ie, improved libido and sexual satisfaction, 
but not by those taking fluoxetine. Furthermore, there were no 
statistically significant increases in mean Hamilton depression 
scores after discontinuation of the SSRIs.
Keltner et al41 suggests that drug holidays may impair 
therapeutic efficacy and lead to withdrawal symptoms. Drug 
holidays may be seen as an exercise in manipulating antide-
pressant half-life. Drugs such as fluoxetine, with a longer 
half-life, will need a longer drug holiday to ensure adequate 
excretion for sexual activity to occur. However, the longer 
the drug holiday the higher the risk of depressive symptoms 
recurring. Short half-life drugs, eg, venlafaxine, may be 
better with regards to facilitating sexual activity; however, 
again the risk of depressive symptoms reasserting themselves 
increases due to the short half life. Drug holidays also carry 
the risk of the client experiencing withdrawal symptoms 
associated with their particular medication. In this event such 
withdrawal symptoms may render the individual unable to 
engage in sexual activity.
A drug holiday is a precursor to sexual activity. Therefore 
the mechanization of scheduling sexual activity so that the 
drug holiday can be introduced may be another drawback of 
this approach. Timetabling is no substitute for romance that 
partners may appreciate as part of their sexual cycle. Setting 
deadlines like this may also increase ‘performance’ anxiety 
which might further compound the problem. The partner will 
also need to be educated about the condition if drug holidays 
are to be introduced as they may be able to give corroborative 
information regarding their effectiveness.
Cognitive behavioral therapy
Counseling therapies such as cognitive behavioral therapy 
(CBT) may be used in a biopsychosocial approach to sexual 
dysfunction. CBT focuses on current issues that are causing 
present problems. As such, it can help people change how 
they think in order to increase positive coping. CBT breaks 
problems down so that individuals can see the links between 
thoughts, feelings, and behavior.
While CBT is a recognized nonpharmacological inter-
vention for a range of psychiatric disorders including 
depression,62 there is little evidence of effectiveness of CBT 
for antidepressant-associated sexual dysfunction. Indeed 
while CBT alone may not be wholly appropriate for manag-
ing the sexual dysfunction, it may be useful in managing 
negative feelings that may have a hugely negative impact 
on the individual’s self esteem and self image. Feelings of 
sexual inadequacy may further compound any depressive 
illness and may put the client at risk of noncompliance. In 
CBT, clients can talk about the emotional impact of the 
sexual dysfunction and get psychological and emotional 
support, while still adhering to treatment regimes. Another 
key factor in CBT will be education of the client regarding 
their sexual dysfunction. This may help reduce catastrophic 
thinking and even prepare for possible future events should 
they arise.
A CBT action plan would seek to challenge these 
negative thoughts in order to enhance self image and self 
esteem. This approach requires both tact and expertise 
as the problem may be seen to be the medication not the 
sexual dysfunction. Part of this overall psycho-education 
should involve the partner who may be equally affected. Sex 
therapy or ‘couples’ counseling would be another alterna-
tive, which again would focus not on the core problem of 
sexual dysfunction but on how the couple can cope with 
its consequences. The unaffected partner will also need 
education so that they can be reassured that the sexual 
dysfunction is not related to a disinterest in them but as a 
result of medication.
The overall management of sexual dysfunction will 
involve pre- and post-test sexual dysfunction and depres-
sion surveys. This will test the efficacy of any intervention 
in reducing sexual dysfunction and how interventions affect 
the depressive illness. The conundrum for managing sexual 
dysfunction is what is more important in antidepressant 
treatment – the threshold for efficacious treatment of depres-
sion or managing the threshold of adverse drug reactions 
such as sexual dysfunction. This will evidentially need to be 
decided on a case by case basis.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Conclusion
Depression is a common mental health problem for which 
a key intervention is antidepressant medication. Although 
there is extensive evidence that antidepressants, especially 
the SSRI group, cause sexual dysfunction in both men and 
women, estimating the exact prevalence is difficult. The sex-
ual problems reported are extensive, ranging from decreased 
sexual desire, decreased sexual excitement, diminished or 
delayed orgasm, to erection or delayed ejaculation problems. 
In addition, there are a number of anecdotal accounts and 
case reports of sexual side effects, such as priapism, painful 
ejaculation, penile anesthesia, decreased nocturnal erections, 
and spontaneous ejaculation in men; and loss of sensation 
in the vagina and nipples, persistent genital arousal, and 
nonpuerperal lactation or galactorrhea in women.
Tackling the problem of antidepressant-induced sexual dys-
function is complex and requires partnership between research 
and practice. While some evidence regarding pharmacological 
management of antidepressant-associated sexual dysfunction 
exists, Taylor et al54 suggest that this is rather limited and insuf-
ficient to formulate a clinical guideline. The first step in manag-
ing antidepressant-induced sexual dysfunction is assessment. 
For many practitioners this may be challenging given the taboo 
that surrounds sex and sexual health. Taking a sexual history 
might be awkward for clinicians and clients alike. However 
as clinicians make this a routine part of their practice for this 
specific client group, they will enhance their skills and practice, 
transforming their awkwardness into expertise, which will 
ensure clients feel well attended to and able to discuss issues 
openly. Initial awkwardness will be a small price to pay for 
enhancing clinical practice and the quality of client care in this 
area. Waiting for clients to break the silence and raise their con-
cerns may leave many clients isolated, confused, and distressed 
or fearful – not just of the drugs, but of engaging in intimate 
relationships. Good assessment will generate good information 
that will enhance effective clinical decision making.
Treating and managing antidepressant-induced sexual 
dysfunction requires a holistic approach as sufferers may be 
skeptical of pharmacological only remedies. There is evi-
dence that bupropion and nefazodone, compared with SSRI 
group, are far less likely to cause sexual dysfunction, and that 
sildenafil will improve erectile dysfunction in men. However, 
nonpharmacological interventions such as sex therapy, CBT, 
and homeopathic remedies should be considered within 
practice and in further research.
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